Grifols SA - Company Profile

Powered by

All the data and insights you need on Grifols SA in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Grifols SA Strategy Report

  • Understand Grifols SA position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Grifols SA: Overview

Select Item

Related keylists

Grifols SA (Grifols) is a pharmaceutical and chemical manufacturing company engaged on enhancing the health and well-being of patients worldwide. It is focused on research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. Grifols offers biological materials for clinical trials, biotechnology research, manufacturing pharmaceutical and diagnostic products. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers its products to hospitals, pharmacies and healthcare professionals. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain.

 Gain a 360-degree view of Grifols SA and make more informed decisions for your business Gain a 360-degree view of Grifols SA and make more informed decisions for your business Find out more
Headquarters Spain
Address C/ Jesus Y Maria, 6, Barcelona, Barcelona , 08022
Website www.grifols.com
Telephone 34 935 710000
No of Employees 23,245
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange GRF (MCE)
Revenue (2022) $6.4B 22.9% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 10.4% (2022 vs 2021)
Market Cap* $9.2B
Net Profit Margin (2022) XYZ -10.4% (2022 vs 2021)
* As of and is in US$
View Grifols SA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Grifols SA premium industry data and analytics

210+

Clinical Trials

Determine Grifols SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

110+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Grifols SA’s relevant decision makers and contact details.

100+

Catalyst Calendar

Proactively evaluate Grifols SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

80+

Pipeline Drugs

Identify which of Grifols SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Marketed Drugs

Understand Grifols SA’s commercialized product portfolio to stay one step ahead of the market.

15+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

10+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

2

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Grifols SA (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Grifols SA’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services Brands
Bioscience: Plasma Testing Albutein
Plasma Derivative Products Clinical Diagnostics Alphanate
Diagnostic: Testing Services Anbinex
XYZ XYZ XYZ
XYZ XYZ XYZ
XYZ XYZ XYZ
Understand Grifols SA portfolio and identify potential areas for collaboration Understand Grifols SA portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 New Products/Services In November, the company launched its new Grifols sCD38 solution.
2023 Contracts/Agreements In October, the company's subsidiary and GigaGen expanded its contract with the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to develop synthetic human antibody treatments for botulinum neurotoxins.
2023 New Products/Services In June, the company launched XEMBIFY in Spain.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Grifols SA Takeda Pharmaceutical Co Ltd CSL Ltd Omnicell Inc Abeona Therapeutics Inc
Headquarters Spain Japan Australia United States of America United States of America
City Barcelona Chuo-Ku Melbourne Santa Clara Cleveland
State/Province Barcelona Tokyo Victoria California Ohio
No. of Employees 23,245 49,095 32,065 4,230 57
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Thomas Glanzmann Chief Executive Officer; Chairman Executive Board 2023 -
Raimon Grifols Roura Chief Corporate Officer; Vice Chairman Executive Board 2023 59
Victor Grifols Deu Chief Operating Officer; Director Executive Board 2023 -
Alfredo Arroyo Guerra Chief Financial Officer Senior Management 2013 66
Maria Teresa Rione Llano Chief Communications Officer Senior Management 2021 58
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into Grifols SA key executives to enhance your sales strategy Gain insight into Grifols SA key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward